Baylor Scott & White Health played a leading role at the 43rd Annual Meeting & Scientific Sessions of The International Society for Heart and Lung Transplantation (ISHLT), held April 19-22, 2023, in Denver, Colorado. More than 3,600 members from around the world gathered to exchange ideas and collaborate on the latest science.
Baylor Scott & White clinicians were responsible for more than 20 presentations on recent advances in the field of advanced heart failure and heart transplant. Topics included the use of extended criteria donors, new and more effective organ preservation technologies, a new surveillance method for heart transplant rejection and management of patients with left ventricular assist devices.
Presenters from Baylor Scott & White included Shelley Hall, MD, FACC, FHFSA, FAST, chief of transplant cardiology, mechanical circulatory support and advanced heart failure, Baylor University Medical Center (Baylor Dallas), part of Baylor Scott & White Health, Dan Meyer, MD, chief of cardiac transplantation and advanced cardiac circulatory support, Baylor Dallas, and Timothy George, MD, a cardiothoracic surgeon on the medical staff at Baylor Scott & White The Heart Hospital Baylor Plano.
Baylor Scott & White Annette C. and Harold C. Simmons Transplant Institute hosts conference on donation after circulatory death
While the number of organ donations after circulatory death (DCD) continues to grow in the United States and worldwide, it is yet to be accepted universally as a viable option to serve patients on the waiting list. Donation after circulatory death was the topic of the 7thInnovations in Transplant Summit, hosted April 22 and 23 by Baylor University Medical Center (Baylor Dallas), part of Baylor Scott & White Health.
Four pillars of heart failure therapy should be rapidly and simultaneously introduced
Known as the “four pillars” of heart failure therapy, these medications are beta blockers, angiotensin receptor-neprilysin inhibitors (ARNIs), mineralcorticoid receptor antagonists (MRAs) and sodium-glucose co-transporter 2 Inhibitors (SGLT2i). The latest clinical evidence shows patients with heart failure should be put on these drugs all at once.
Baylor Scott & White opens heart failure outreach in Shreveport
To provide advanced heart failure treatment to patients in north Louisiana, Baylor Scott & White Health has established an outreach clinic in Shreveport.
Baylor Scott & White Heart Transplant team excels at American Transplant Congress
Baylor Scott & White Research Institute investigators and clinicians on the medical staff at Baylor Dallas were responsible for more than 10 presentations, scheduled talks, education sessions and discussions. Members of the heart transplant team also received several notable recognitions at the meeting.